Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 70518-4553

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-4553). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (546b07bd 7dba 49c9 8caf 7914600d4d19 01)

Chemical structure of divalproex sodium, showing the sodium salt and its associated acid form in an extended polymeric representation.*

FDA Label Image

Image (546b07bd 7dba 49c9 8caf 7914600d4d19 02)

A line graph comparing the percentage reduction in CPS (complex partial seizure) rate between divalproex sodium delayed-release tablets and placebo. The x-axis shows the percentage of patients from 100 to 0, and the y-axis depicts percent reduction in CPS rate from -100% to 100%, with labels indicating improvement, no change, and worsening. The divalproex sodium line generally indicates greater improvement than the placebo.*

FDA Label Image

Image (546b07bd 7dba 49c9 8caf 7914600d4d19 03)

A line graph comparing the percent reduction in CPS rate versus the percent of patients for high dose and low dose divalproex sodium delayed-release tablets. The graph includes improvement and worsening indicators, showing trends in patient response to different dosages.*

FDA Label Image

Image (546b07bd 7dba 49c9 8caf 7914600d4d19 04)

A bar chart comparing the effects of placebo and divalproex sodium extended-release tablets. The chart shows two bars, one indicating the placebo effect and the other a higher value for divalproex sodium, with labels on the bars and a statistical significance marker (p=0.006).*

FDA Label Image

Remedy_label (Remedy Label)

Label for divalproex sodium extended-release tablets, 500 mg strength, containing 30 tablets per package. The label indicates the product is repackaged by RemedyRepack Inc., Indiana, PA. Manufacturer information is listed as Unichem Labs Ltd., Goa, India. The label includes storage instructions and standard warnings about keeping medication out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.